{"id":"W3018979351","doi":"10.1016/j.annonc.2020.04.010","title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":461,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Foundation Medicine; Pharmacyclics; EMD Serono; Ipsen; Eisai; Merck KGaA; Exelixis; GlaxoSmithKline; Memorial Sloan-Kettering Cancer Center; Astellas Pharma; Alexion Pharmaceuticals; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Axitinib; Sunitinib; Avelumab; Javelin; Renal cell carcinoma; Internal medicine; Oncology; Urology; Nivolumab; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005953114,0.0009368517,0.002338564,0.0005430019,0.0003943756,0.001550318,0.0007550889,0.000816195,0.003934093],"category_scores_gemma":[0.004495905,0.0004103137,0.003314746,0.0006156731,0.0003749498,0.001090787,0.0004287454,0.002355586,0.0005920437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007527636,"about_ca_system_score_gemma":0.001168156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006300263,"about_ca_topic_score_gemma":0.002618141,"domain_scores_codex":[0.9973827,0.00154512,0.0002073426,0.0002485065,0.0003708883,0.0002454159],"domain_scores_gemma":[0.996876,0.001007402,0.00110106,0.0002785585,0.0002599337,0.0004771247],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7787748,0.00535524,0.02800029,0.002910393,0.01522354,0.0002123986,0.0002013783,0.006401269,0.008842427,0.000631224,0.02367085,0.1297761],"study_design_scores_gemma":[0.671778,0.1077159,0.1543898,0.0004516609,0.02508574,0.0009539638,0.0001233904,0.004248247,0.007209445,0.001706683,0.02615619,0.0001808142],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9079792,0.03073007,0.002455519,0.002844653,0.0008035247,0.003776003,0.0370991,0.0003424123,0.01396939],"genre_scores_gemma":[0.9514979,0.005100131,0.002823428,0.001943419,0.000622789,0.002827724,0.03137713,0.00008226849,0.003725131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005953114,"threshold_uncertainty_score":0.03148347,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1030485803041408,"score_gpt":0.3299452875303705,"score_spread":0.2268967072262297,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}